Search

everythinglearnresearchcommunity

for

Search:↓

New pyrazole-based inhibitors show promise for treating metabolic diseases and other conditions.

Deucravacitinib improves symptoms and reduces inflammation in Lichen Planopilaris.

ITK inhibitors may effectively treat alopecia areata.

New treatments like JAK inhibitors offer hope for better alopecia areata management.

JAK inhibitors show promise in treating moderate to severe alopecia areata.

JAK/STAT inhibitors show promise for skin diseases but aren't yet approved.

New cancer drugs can cause skin side effects like rashes, dry skin, hair changes, and nail problems.

Combining ciclosporin and simvastatin can cause severe kidney damage.

Selumetinib causes fewer and less severe skin issues in children than binimetinib.

Ivarmacitinib effectively regrows hair in severe alopecia areata.

Cyclosporin A and FK506 can start new hair growth without needing immunosuppression.

Janus kinase inhibitors are effective and generally safe for treating hair loss in adults with alopecia areata.

Two drugs, tofacitinib and ruxolitinib, may help regrow hair by activating hair follicles.

Ruxolitinib helps protect skin stem cells and keeps skin healthy in mice with skin GVHD.

Both tofacitinib and ruxolitinib are effective and tolerable for treating alopecia areata.

Oral baricitinib and ruxolitinib are effective and safe for treating alopecia areata.

JAK inhibitors like baricitinib are a new FDA-approved treatment for alopecia areata, but safety data is incomplete.

Tyrosine Kinase Inhibitors are effective against cancer but can cause skin, digestive, and blood side effects, including hair loss.

DS-2325a is safe and well-tolerated, supporting further development for Netherton Syndrome treatment.

Inhibiting TYK2 can restore hair growth in alopecia areata.

Secukinumab reduces immune activity in hidradenitis suppurativa skin.

Experts created guidelines for who in Australia can get subsidized JAK inhibitor therapy for alopecia areata.

JAK inhibitors are effective for severe alopecia areata but need better strategies for long-term use and personalized treatment.

BMS-470539 reduces skin fibrosis and inflammation.

Janus kinase inhibitors effectively treat alopecia areata but may cause relapses and have long-term safety concerns.

Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.

JAK inhibitors might help treat alopecia areata.

Tofacitinib helped regrow hair in a lupus patient with alopecia.

Capivasertib improves survival in certain breast cancer cases but requires careful management of side effects.

Upadacitinib significantly improved alopecia universalis and psoriatic arthritis in a patient.